Prothena Corporation plc (PRTA) announced that its board has authorized a share repurchase plan allowing the company to buy back up to $100 million of its outstanding ordinary shares.
As of December 31, 2025, Prothena reported $308.4 million in cash, cash equivalents, and restricted cash, with no debt. Excluding any purchases under the repurchase plan, the company expects to end 2026 with approximately $255 million in cash, cash equivalents, and restricted cash.
The guidance does not factor in the potential to earn up to $105 million in clinical milestone payments from strategic partners in 2026, tied to the advancement of coramitug for ATTR amyloidosis with cardiomyopathy in collaboration with Novo Nordisk, and PRX019 for neurodegenerative diseases in partnership with Bristol Myers Squibb.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.